Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation - PubMed (original) (raw)

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

Nicolaus Kröger et al. Transplantation. 2006.

Abstract

Background: The effect of natural killer (NK) cell alloreactivity on outcome of unrelated stem cell transplantation (SCT) remains controversial. Killer immunoglobulin-like receptors (KIRs) recognize human leukocyte antigen C and B epitopes on target cells, thereby regulating NK cell activity. The KIR genes are polymorphic and two broad haplotypes exist: KIR-haplotype A mainly encode for inhibitory receptors and only for one activating (KIR2DS4), whereas the group B haplotype encodes more for activating KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 und KIR3DS1).

Methods: The impact of KIR ligand mismatch on the number of activating and inhibitory donor KIR genes and on KIR-haplotype was studied on outcome of 142 patients with leukemia, who received standard myeloablative conditioning followed by in vivo T-cell depleted (ATG) unrelated SCT.

Results: In a multivariate analysis KIR ligand mismatch had significantly higher treatment related mortality (RR 2.206, P = 0.03), resulting in reduced overall (RR 2.015, P = 0.02) and disease-free survival (RR 1.924, P = 0.03). In contrast, SCT from donors with group A haplotype (P = 0.003) or with low number of activating KIR genes (P = 0.005) resulted in reduced relapse rate with improved disease-fee survival (P = 0.04). This effect was seen only in acute myeloid leukemia/myelodysplastic syndrome and to a less extent in chronic myeloid leukemia. No effect was seen for acute lymphoblastic leukemia.

Conclusions: After in vivo T-cell depleted (ATG) unrelated stem cell transplantation with donors carrying low number of activating KIR genes (group A KIR haplotype), the risk of relapse is reduced and resulted in a significantly better disease-free survival.

PubMed Disclaimer

Similar articles

• Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
  Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Holowiecki J, Holowiecka-Goral A, Markiewicz M, Kopera M, Karolczyk A, Kyrcz-Krzemien S, Kusnierczyk P. Giebel S, et al. Eur J Haematol. 2009 Oct;83(4):343-56. doi: 10.1111/j.1600-0609.2009.01280.x. Epub 2009 Jun 2. Eur J Haematol. 2009. PMID: 19500138
• Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.
  Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, Yamamoto K, Maruya E, Akatsuka Y, Onizuka M, Sakamaki H, Sao H, Ogawa S, Kato S, Juji T, Sasazuki T, Kodera Y; Japan Marrow Donor Program. Morishima Y, et al. Biol Blood Marrow Transplant. 2007 Mar;13(3):315-28. doi: 10.1016/j.bbmt.2006.10.027. Biol Blood Marrow Transplant. 2007. PMID: 17317585
• The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
  Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S. Bishara A, et al. Tissue Antigens. 2004 Mar;63(3):204-11. doi: 10.1111/j.0001-2815.2004.00182.x. Tissue Antigens. 2004. PMID: 14989709
• Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
  Willemze R, Ruggeri A, Purtill D, Rodrigues CA, Gluckman E, Rocha V; Eurocord and of the European Group of Blood and Marrow Transplantation. Willemze R, et al. Best Pract Res Clin Haematol. 2010 Jun;23(2):283-90. doi: 10.1016/j.beha.2010.05.005. Best Pract Res Clin Haematol. 2010. PMID: 20837340 Review.
• KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation.
  Malmberg KJ, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. Malmberg KJ, et al. Mol Immunol. 2005 Feb;42(4):531-4. doi: 10.1016/j.molimm.2004.07.037. Mol Immunol. 2005. PMID: 15607809 Review.

Cited by

• Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
  Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F. Shi J, et al. Br J Haematol. 2008 Dec;143(5):641-53. doi: 10.1111/j.1365-2141.2008.07340.x. Epub 2008 Oct 16. Br J Haematol. 2008. PMID: 18950462 Free PMC article.
• Clinical utility of natural killer cells in cancer therapy and transplantation.
  Knorr DA, Bachanova V, Verneris MR, Miller JS. Knorr DA, et al. Semin Immunol. 2014 Apr;26(2):161-72. doi: 10.1016/j.smim.2014.02.002. Epub 2014 Mar 5. Semin Immunol. 2014. PMID: 24618042 Free PMC article. Review.
• Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients.
  Impola U, Turpeinen H, Alakulppi N, Linjama T, Volin L, Niittyvuopio R, Partanen J, Koskela S. Impola U, et al. Front Immunol. 2014 Aug 25;5:405. doi: 10.3389/fimmu.2014.00405. eCollection 2014. Front Immunol. 2014. PMID: 25202311 Free PMC article.
• Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children.
  Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Müller I, Handgretinger R, Lang P. Pfeiffer MM, et al. Haematologica. 2010 Aug;95(8):1381-8. doi: 10.3324/haematol.2009.021121. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145268 Free PMC article.
• NK cell therapy for hematologic malignancies.
  Mehta RS, Randolph B, Daher M, Rezvani K. Mehta RS, et al. Int J Hematol. 2018 Mar;107(3):262-270. doi: 10.1007/s12185-018-2407-5. Epub 2018 Jan 27. Int J Hematol. 2018. PMID: 29383623 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program